ReviewJournal of virology2026
Epstein-Barr virus receptors: classification, functional mechanisms, and pathogenic implications.
Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epstein-Barr virus (EBV) is a widely prevalent γ-herpesvirus that primarily infects human B cells and epithelial cells. It is closely associated with the development of various lymphomas and epithelial cancers, posing a significant threat to human life and health. The infection process of EBV relies on interactions between the virus and specific receptors on the surface of host cells, including CD21, NRP1, EphA2, and, more recently, discovered receptors such as R9AP and DSC2. Currently, no specific drugs targeting EBV have been developed, making further research on EBV receptors particularly crucial. This review summarizes the classification, structural characteristics, and molecular mechanisms of the EBV receptors identified to date and compares the differential pathways through which these receptors function in B cells and epithelial cells. Furthermore, this review discusses the potential applications of targeting EBV receptors in antiviral therapy, vaccine development, and cancer immunotherapy, while addressing the limitations of current research and future directions. The aim is to broaden the scope of future research in the field of EBV receptors and provide new perspectives for the prevention and treatment of EBV-associated diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.